Private finance: Asgard Therapeutics, Vensica Therapeutics, Sigrid Therapeutics, GlycoEra, Home Biosciences, illumigyn, Prilenia Therapeutics

Sigrid Therapeutics CEO Sana Alajmovic

Netherlands: Prilenia Therapeutics, a clinical stage biotech company, raised US$43m in Series B funding, bringing the total capital raised since its founding in September 2018 to US$133.5m. The round was led by Sands Capital with participation from Forbion and Morningside, Amplitude Ventures, Sectoral Asset Management, Talisman and the ALS Investment Fund. The company intends to…

You must be a HMI Subscriber to view this content.

Subscribe Now »